184 related articles for article (PubMed ID: 34154337)
1. Response to the rechallenge of combination immunotherapy in a patient with late-stage gastric cancer: case report.
Zhang Z; Cheng S; Qi C; Zhang X; Peng Z; Shen L
Ann Palliat Med; 2022 Feb; 11(2):818-826. PubMed ID: 34154337
[TBL] [Abstract][Full Text] [Related]
2. Programmed Cell Death Protein 1 Blockade Elicits Ongoing Remission in 2 Cases of Refractory Epstein-Barr Virus-Associated Metastatic Gastric Carcinoma.
Masetti M; Lindinger M; Lorenzen S
Oncol Res Treat; 2022; 45(6):375-379. PubMed ID: 35220300
[TBL] [Abstract][Full Text] [Related]
3. Current status of immune checkpoint inhibitors for gastric cancer.
Kono K; Nakajima S; Mimura K
Gastric Cancer; 2020 Jul; 23(4):565-578. PubMed ID: 32468420
[TBL] [Abstract][Full Text] [Related]
4. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
5. The current management and biomarkers of immunotherapy in advanced gastric cancer.
Chang X; Ge X; Zhang Y; Xue X
Medicine (Baltimore); 2022 May; 101(21):e29304. PubMed ID: 35623069
[TBL] [Abstract][Full Text] [Related]
6. Case report: Long response to PD-1 blockade after failure of trastuzumab plus chemotherapy in advanced Epstein-Barr virus-associated gastric cancer.
Pan Y; Lu L; Liu H; Chen D; Han N; Yao R; Wang X; Gao X; Yu J; Chen L; Zhou F; Hao G; Lu Y; Li M; He G; Kang F; Li Z; Tang Y; Zhang J; Wei L; Nie Y
Front Immunol; 2022; 13():1003859. PubMed ID: 36353623
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors and cellular immunotherapy for advanced gastric, gastroesophageal cancer: a long pathway.
Cheng R; Li B; Wang H; Zeng Y
Clin Transl Oncol; 2023 Nov; 25(11):3122-3138. PubMed ID: 37036597
[TBL] [Abstract][Full Text] [Related]
8. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
Taieb J; Moehler M; Boku N; Ajani JA; Yañez Ruiz E; Ryu MH; Guenther S; Chand V; Bang YJ
Cancer Treat Rev; 2018 May; 66():104-113. PubMed ID: 29730461
[TBL] [Abstract][Full Text] [Related]
9. Current Status in Rechallenge of Immunotherapy.
Hu H; Wang K; Jia R; Zeng ZX; Zhu M; Deng YL; Xiong ZJ; Tang JN; Xie H; Wang Y; Zhang P; Zhou J
Int J Biol Sci; 2023; 19(8):2428-2442. PubMed ID: 37215995
[TBL] [Abstract][Full Text] [Related]
10. Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer.
Kang BW; Chau I
ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32817133
[TBL] [Abstract][Full Text] [Related]
11. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
[TBL] [Abstract][Full Text] [Related]
12. Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma.
Koemans WJ; Chalabi M; van Sandick JW; van Dieren JM; Kodach LL
Cancer Lett; 2019 Feb; 442():279-286. PubMed ID: 30419350
[TBL] [Abstract][Full Text] [Related]
13. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer.
Zeng Z; Yang B; Liao Z
Future Oncol; 2021 Apr; 17(12):1553-1569. PubMed ID: 33397136
[TBL] [Abstract][Full Text] [Related]
14. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
[TBL] [Abstract][Full Text] [Related]
15. The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer.
Wei XL; Liu QW; Liu FR; Yuan SS; Li XF; Li JN; Yang AL; Ling YH
Oncoimmunology; 2021; 10(1):1938381. PubMed ID: 34235004
[TBL] [Abstract][Full Text] [Related]
16. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy.
Booth ME; Smyth EC
BioDrugs; 2022 Jul; 36(4):473-485. PubMed ID: 35384619
[TBL] [Abstract][Full Text] [Related]
18. Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer.
Dai C; Geng R; Wang C; Wong A; Qing M; Hu J; Sun Y; Lo AW; Li J
Mol Oncol; 2016 Dec; 10(10):1551-1558. PubMed ID: 27720576
[TBL] [Abstract][Full Text] [Related]
19. Current status of immunotherapy for advanced gastric cancer.
Kawazoe A; Shitara K; Boku N; Yoshikawa T; Terashima M
Jpn J Clin Oncol; 2021 Jan; 51(1):20-27. PubMed ID: 33241322
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer.
Kubota Y; Kawazoe A; Sasaki A; Mishima S; Sawada K; Nakamura Y; Kotani D; Kuboki Y; Taniguchi H; Kojima T; Doi T; Yoshino T; Ishii G; Kuwata T; Shitara K
Clin Cancer Res; 2020 Jul; 26(14):3784-3790. PubMed ID: 32156744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
